OBJECTIVES: In 2011, various legislative measures were adopted in Slovakia regarding drug policy. The aim of the submitted work is to evaluate links between the introduction of regulations and the consumption of antihypertensive drugs (AH), expenditures and patient co-payments. METHODS: We evaluated data on drugs consumption based on IMS Data. Patient co-payments data were taken from the National Health Information database. When evaluating the average amount of co-payments, we applied a weighted average, which takes into account the level of co-payment and consumption. RESULTS: The consumption of AH (in DOT) increased continually in 2006-2013 (+36%) and the turnover of AH dropped by 4% as a consequence of introducing new regulations. The impact of new regulations was expressed foremost in the consumption of RAS inhibitors, where the decrease in turnover after introduction of clusters in 2012 was 14%. In the evaluated period, the final price of AH was reduced by 35% (from € 8.86 to € 5.78) and the reimbursement was reduced by 52% (from € 7.87 to € 3.76). At the same time, there was an increase in average co-payments by 105% (from € 0.99 to € 2.03). In the evaluated period, the patient co-payment for a fixed AH almost quadrupled (from € 1.05 to € 4.05). The patient paid an average of € 0.93 more for one pack of fixed AH than for a free combination. After the introduction of regulations, the consumption of fixed combinations grew at a slower pace than in the case of monocomponents.   CONCLUSIONS: The legislative changes in drug policy had a significant impact on the consumption of antihypertensive drugs and on the expense of hypertension treatment. It is necessary to monitor long-term and analyse the impacts of regulations on the prescription of AH and to evaluate factors that can influence the success of hypertension treatment.